GeNeuro appoints MS clinical development expert Dr. David Leppert as Chief Medical Officer

GeNeuro appoints MS clinical development expert Dr. David Leppert as Chief Medical Officer

Geneva, Switzerland, April 21, 2020–7:30am CEST –GeNeuro (Euronext Paris: CH0308403085 -GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseasessuch as multiple sclerosis , today announcesthe appointment of the experienced medical and industry professional Prof. David Leppert, MD and Professor of Neurology, as Chief Medical Officer.

For more information, http://www.geneuro.com/data/news/GeNeuro-PR-CMO-appointment-EN.pdf